BridgeBio Phase 3 data for ATTR CM drug published in NEJM

GreenApple78 BridgeBio Pharma ( NASDAQ: BBIO ) said positive results from its Phase 3 ATTRibute CM study for its drug acoramidis in the treatment of transthyretin amyloid cardiomyopathy, or ATTR CM, have been published in the New England Journal of Medicine. The biotech company released topline results from the study in July and presented additional data at the European Society of Cardiology Congress in August and the American Heart Association Scientific Sessions in November, according to a statement .

BridgeBio submitted a market application to the FDA for acoramidis in December. It intends to submit applications for market approval from additional regulatory bodies this year. If approved, acoramidis would compete against Pfizer's ( PFE ) Vyndamax/Vyndaquel, also known as tafamidis, which is also approved to treat the condition.

More on BridgeBio Pharma BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner BridgeBio Pharma: Taking Some Profits BridgeBio submits FDA market application for ATTR CM drug BridgeBio draws Buy rating at Cantor citing 100% upside Seeking Alpha’s Quant Rating on BridgeBio Pharma.